Review



tki inhibitor gilteritinib  (MultiTarget Pharmaceuticals)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MultiTarget Pharmaceuticals tki inhibitor gilteritinib
    Tki Inhibitor Gilteritinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tki+inhibitor+gilteritinib/tki+inhibitor+gilteritinib/pm37715310-18-57-82
    Average 90 stars, based on 1 article reviews
    tki inhibitor gilteritinib - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Transformation Assay:

    Article Title: Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
    Article Snippet: .. The ALK- independent resistance mechanisms include activated bypass pathways involving epidermal growth factor receptor (EGFR), cytoplasmic mesenchymal– epithelial transition factor (MET), V- Ki- ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), AXL, and histological transformation.7– 11 The ALKdependent drug insensitivity is associated with secondary mutations in ALK and/or amplification of ALK fusion genes.12– 14 Gilteritinib is a TKI inhibitor developed primarily against FMSlike tyrosine kinase 3 (FLT3) and approved in the treatment of FLT3mutant acute myeloid leukemia (AML).15 However, it is a multitarget compound with a broad range of activity against several tyrosine kinases, including AXL and ALK,16 and is reportedly effective against ALK- rearranged anaplastic large cell lymphoma.17 Furthermore, a recent study demonstrated the efficacy of gilteritinib in sufficiently treating ALK- rearranged NSCLC with acquired resistance to the third- generation ALK- TKI lorlatinib.18 Several double mutations have been identified, which confer tolerance to all approved ALKTKIs, such as I1171N + F1174I and I1171N + L1198H. ..

    Amplification:

    Article Title: Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
    Article Snippet: .. The ALK- independent resistance mechanisms include activated bypass pathways involving epidermal growth factor receptor (EGFR), cytoplasmic mesenchymal– epithelial transition factor (MET), V- Ki- ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), AXL, and histological transformation.7– 11 The ALKdependent drug insensitivity is associated with secondary mutations in ALK and/or amplification of ALK fusion genes.12– 14 Gilteritinib is a TKI inhibitor developed primarily against FMSlike tyrosine kinase 3 (FLT3) and approved in the treatment of FLT3mutant acute myeloid leukemia (AML).15 However, it is a multitarget compound with a broad range of activity against several tyrosine kinases, including AXL and ALK,16 and is reportedly effective against ALK- rearranged anaplastic large cell lymphoma.17 Furthermore, a recent study demonstrated the efficacy of gilteritinib in sufficiently treating ALK- rearranged NSCLC with acquired resistance to the third- generation ALK- TKI lorlatinib.18 Several double mutations have been identified, which confer tolerance to all approved ALKTKIs, such as I1171N + F1174I and I1171N + L1198H. ..

    Activity Assay:

    Article Title: Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
    Article Snippet: .. The ALK- independent resistance mechanisms include activated bypass pathways involving epidermal growth factor receptor (EGFR), cytoplasmic mesenchymal– epithelial transition factor (MET), V- Ki- ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), AXL, and histological transformation.7– 11 The ALKdependent drug insensitivity is associated with secondary mutations in ALK and/or amplification of ALK fusion genes.12– 14 Gilteritinib is a TKI inhibitor developed primarily against FMSlike tyrosine kinase 3 (FLT3) and approved in the treatment of FLT3mutant acute myeloid leukemia (AML).15 However, it is a multitarget compound with a broad range of activity against several tyrosine kinases, including AXL and ALK,16 and is reportedly effective against ALK- rearranged anaplastic large cell lymphoma.17 Furthermore, a recent study demonstrated the efficacy of gilteritinib in sufficiently treating ALK- rearranged NSCLC with acquired resistance to the third- generation ALK- TKI lorlatinib.18 Several double mutations have been identified, which confer tolerance to all approved ALKTKIs, such as I1171N + F1174I and I1171N + L1198H. ..



    Similar Products

    tki inhibitor gilteritinib  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals tki inhibitor gilteritinib
    Tki Inhibitor Gilteritinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tki+inhibitor+gilteritinib/tki+inhibitor+gilteritinib/pm37715310-18-57-82
    Average 90 stars, based on 1 article reviews
    tki inhibitor gilteritinib - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results